For Immediate Release
Chicago, IL – June 16, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: salesforce.com, inc. (
CRM Quick Quote CRM - Free Report) , Shopify Inc. ( SHOP Quick Quote SHOP - Free Report) , AstraZeneca PLC ( AZN Quick Quote AZN - Free Report) , Micron Technology, Inc. ( MU Quick Quote MU - Free Report) and Ecolab Inc. ( ECL Quick Quote ECL - Free Report) . Here are highlights from Tuesday’s Analyst Blog: Top Research Reports for salesforce, Shopify and AstraZeneca
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including salesforce.com, Shopify, and AstraZeneca. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see
all of today’s research reports here >>>
salesforce have underperformed the Zacks Computer Software industry in the year-to-date period (+10.7% vs. +15.9%), but the Zacks analyst sees the company as well positioned to benefit from a robust demand environment as customers are undergoing a major digital transformation.
Moreover, the recent deal to acquire Slack would position the company to be a leader in enterprise team collaboration solution space and better compete with Microsoft’s Teams product. However, unfavorable currency fluctuations along with increasing investments in international expansions and data centers are an overhang on the near-term profitability.
) read the full research report on salesforce here >>> Shopify shares have gained +14.3% over the last six months against the Zacks Internet Services industry’s gain of +27.2%, reflecting the market's skepticism about the company's outlook in the post-pandemic world.
An uptick in Shopify Shipping, Shopify Payments and Shopify Capital has consistently driven the top line. Additionally, partnerships with TikTok, Walmart and Facebook are likely to expand the merchant base. However, higher investments on product development amid stiff competition in the e-commerce space will limit margin expansion in the near term.
) read the full research report on Shopify here >>>
AstraZeneca have gained +17.2% in the past three months against the Zacks Large Cap Pharmaceuticals industry’s gain of +9.7%. The Zacks analyst believes that AstraZeneca’s products like Nexium and Seroquel are facing generic competition, which are weighing on its sales.
However, newer drugs such as Tagrisso and Imfinzi are likely to keep driving revenues. The company also has a strong pipeline with a spate of phase III data readouts lined up for the current year. It has also engaged in external acquisitions and strategic collaborations to boost its pipeline while investing in high growth geographic areas like China.
) read the full research report on AstraZeneca here >>>
Other noteworthy reports we are featuring today include Micron Technology and Ecolab.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss
. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.